Overview

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the antitumor activity, toxicity, and effectiveness of the combination of goserelin (Zoladex) and anastrozole (Arimidex) in the treatment of premenopausal women with hormone receptor positive metastatic carcinoma of the breast.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
AstraZeneca
Treatments:
Anastrozole
Goserelin